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Protein kinase C (PKC)-ε, a component of the serine/threo-
nine PKC family,has been shown to influence the survival and
differentiation pathways of normal hematopoietic cells. Here,
we have modulated the activity of PKC-ε with specific small
molecule activator or inhibitor peptides. PKC-ε inhibitor and
activator peptides showed modest effects on HL-60 matura-
tion when added alone, but PKC-ε activator peptide signifi-
cantly counteracted the pro-maturative activity of tumor necro-
sis factor (TNF)-α towards the monocytic/macrophagic line-
age, as evaluated in terms of CD14 surface expression and
morphological analyses. Moreover, while PKC-ε inhibitor pep-
tide showed a reproducible increase of TNF-related apoptosis
inducing ligand (TRAIL)-induced apoptosis, PKC-ε activator
peptide potently counteracted the pro-apoptotic activity of
TRAIL. Taken together, the anti-maturative and anti-apoptotic
activities of PKC-ε envision a potentially important pro-
leukemic role of this PKC family member.
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A
ctivation of all protein kinase C (PKC) fam-
ily of serine and threonine isoenzymes is
associated with binding to the negatively
charged phospholipids, phosphatidylserine, while
different PKC isozymes have varying sensitivities to
Ca
2+ and lipid-derived second messengers such as
diacylglycerol (Gonelli et al., 2009). Upon activa-
tion, PKC isozymes translocate from the soluble to
the particulate cell fraction, including cell mem-
brane, nucleus and mitochondria (Gonelli  et al.,
2009).PKC primary sequence can be broadly sepa-
rated into two domains: the N-terminal regulatory
domain and the conserved C-terminal catalytic
domain.The regulatory domain of PKC is composed
of the C1 and C2 domains that mediate PKC inter-
actions with second messengers, phospholipids, as
well as inter and intramolecular protein-protein
interactions.Differences in the order and number of
copies of signaling domains,as well as sequence dif-
ferences that affect binding affinities, result in the
distinct activity of each PKC isozyme (Gonelli et
al., 2009).
In recent years, a series of peptides derived from
PKC have been shown to modulate its activity by
interfering with critical protein-protein interactions
within PKC and between PKC and PKC-binding
proteins (Brandman et al., 2007, Souroujon and
Mochly-Rosen, 1998). Focusing on PKC-ε isozyme
and using a rational approach, one C2-derived pep-
tide that acts as an isozyme-selective activator
(Dorn  et al., 1999)  and another that acts as a
selective inhibitor (Johnson et al., 1996) of PKC-ε,
have been identified.These findings are particularly
interesting since besides being involved in the phys-
iology of normal cardiac (Braun and Mochly-
Rosen,2003,Johnson et al.,1996,Li et al.,2006),
hematopoietic (Gobbi et al.,2009,Mirandola et al.,
2006, Racke et al., 2001), and neuronal (Borgatti
et al., 1996) cell models, mounting experimental
evidences have linked altered PKC-ε functions to
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                  solid tumor development (Okhrimenko et al.,2005,
Gillespie et al., 2005, Lu et al., 2006).Therefore,
taking advantage of the recent availability of small
molecule peptides able to activate or inhibit specif-
ically PKC-ε by disrupting protein/protein interac-
tions (Dorn et al., 1999, Johnson  et al., 1996),
which open important therapeutic perspectives, we
have investigated the effects of both PKC-ε activa-
tor and PKC-ε inhibitor peptides on the maturation
and survival of leukemic cells,using as a model sys-
tem the HL-60 myeloblastic leukemia cell line,
which can be induced to undergo terminal differen-
tiation or apoptotic cell death by a variety of chem-
ical and biological agents (Breitman et al., 1980,
Zauli et al., 1996).
Materials and Methods
Cells and reagents
HL-60 cells,were cultured in RPMI-1640 (Gibco
BRL, Grand Island, NY) supplemented with 10%
fetal bovine serum (FBS; Gibco) and seeded at an
optimal cell density of 0.8-1.0×10
6 cells/mL before
treatments. A PKC-ε-selective agonist octapeptide,
ψε receptor for activated C-kinase (ψε RACK),
derived from a PKC-ε sequence homologous to its
anchoring protein, RACK-ε: [HDAPIGYD; PKC-ε
(85-92)], was synthesized and purified (97%) at
Inbios S.r.l. (Napoli, Italy). A PKC-ε-selective
antagonist peptide, eV1-2 [(EAVSLKPT; PKC-ε
(14-21)],and a negative control peptide,scrambled
eV1-2 (LSETKPAV), were purchased from
Calbiochem (Darmstadt, Germany).
HL-60 cells were treated with predetermined
optimal concentrations of PKC-ε agonist
octapeptide (activator), PKC-ε antagonist pep-
tide (inhibitor) and scrambled peptide (22
µg/mL); recombinant TNF-related apoptosis
inducing ligand (TRAIL) (0.1 µg/mL), prepared
as previously described (Zauli et al., 2003), or
recombinant tumor necrosis factor (TNF)-α
(0.1 µg/mL) (R&D Systems, Minneapolis, MN,
USA), used either alone or in combination. In
some experiments, HL-60 were treated with 10
–7
M phorbol myristate acetate (PMA), purchased
from Sigma Chemicals (Minneapolis, MN). The
PKC-ε catalytic activity was evaluated by using
the PKCε KinEASE™ FP fluorescein green assay
kit,used according to the manufacturer’s instruc-
tions (Millipore, Billerica, MA, USA).
Assessment of cell maturation and apoptosis
At different times (1-3 days) post-treatment with
PKC-ε activator and inhibitor peptides, TNF-α or
TRAIL, both maturation-inducing activity and cyto-
toxicity were assessed. In particular, samples were
analyzed by: (1) monitoring cell surface antigen
expression of CD14 and CD11b myeloid antigens
(Todd et al., 1981, Zhang et al., 1994); (2) evaluat-
ing the degree of apoptosis by Annexin V/propidium
iodide (PI) double staining and flow cytometry analy-
sis and/or poly(ADP)ribose polymerase (PARP)
cleavage in Western blot, as previously described
(Borgatti et al., 1997,Vitale et al., 1997). For flow
cytometry analyses, both the Annexin V-fluorescein
isothiocyanate (FITC)/PI apoptosis kit and the
CD11b and CD14 phycoerythrin (PE) or FITC-con-
jugated antibodies (Abs) were purchased from
Immunotech (Marseille, France). Unspecific fluores-
cence was assessed by using isotype-matched con-
trols; (3) examining the morphology of the cells by
staining with May-Grunwald-Giemsa solution fol-
lowed by light microscopy examination (Secchiero et
al., 2002, Secchiero et al., 2007); (4) counting the
total number of viable cells by trypan blue dye exclu-
sion; (5) using the 3-(4,5-dimethilthiazol-2yl)-2,5-
diphenyl tetrazolium bromide (MTT) colorimetric
assay (Roche Diagnostics Corporation, Indianapolis,
IN, USA).
Western blot analysis
Cells were lysed in a buffer containing 50 mM Tris-
HCl, pH 8.0, 250 mM NaCl, 0.5% NP40,
2 mM sodium orthovanadate, 1 mM phenylmethyl-
sulfonyl fluoride (PMSF),and 2 µg/mL of pepstatin.
For Western blot analysis, 50-70 µg of protein were
resolved on SDS-polyacrylamide gels and trans-
ferred to nitrocellulose membranes. Blots were incu-
bated with monoclonal Abs anti-DNA repair enzyme
PARP (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) or anti-actin (Sigma Aldrich, St. Louis, MO,
USA) used for loading control (Milani et al.,2003).
Membranes were washed and further incubated for
one hour at room temperature with peroxidase-con-
jugated secondary Ab (Sigma). Detection was then
performed using the Renaissance chemiluminescent
ECL kit (NEN Dupont, Boston, MA, USA). Protein
levels were densitometrically analysed by the
ImageQuant software (Molecular Dynamics,
Sunnyvale, CA, USA). Multiple film exposures were
used to verify the linearity of the samples analyzed
and to avoid saturation of the film.
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Data were analyzed using the two-tailed
Student’s t-test.Statistical significance was defined
as p<0.05.
Results
PKC-ε activator peptide counteracts maturation
induced by TNF-α
The effect of pre-determined optimal concentra-
tions of specific peptides to modulate the catalytic
activity of PKC-ε was initially evaluated by using a
kit assay specific for PKC-ε.As shown in Figure 1,the
PKC-ε activator peptide significantly (p<0.05) pro-
moted PKC-ε catalytic activity.On the other hand,the
PKC-ε inhibitor peptide depressed the basal levels of
PKC-ε catalytic activity and profoundly inhibited
(p<0.05) the activation of PKC-ε induced by PMA.
Since an important anti-leukemic strategy is to pro-
mote terminal growth arrest and maturation of acute
myeloid leukemia (AML) blasts, in the first group of
experiments, we have investigated whether the PKC-
ε activator and inhibitor peptides were able to modu-
late the phenotypic profile and morphology of HL-60
cells,after treatment with TNF-α,which represents a
powerful inducer of maturation along the monocytic/
macrophagic lineage (Secchiero et al., 2003). As
shown in Figure 2A and 2B,TNF-α markedly up-reg-
ulated the surface expression of CD14, which repre-
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Figure 1. Validation of the PKC-ε ε activator and inhibitor peptides
in HL-60 cells. HL-60 cells were incubated with pre-determined
optimal concentrations (22 µg/mL) of PKC-ε ε activator (act) or
inhibitor (inh) peptides, or with scrambled (scr) peptides used as
negative controls for 8 hours. In parallel, PMA was used as posi-
tive control, for its ability to activate PKC-ε ε. PKC-ε ε catalytic activ-
ity, evaluated as described in Materials and Methods, is
expressed as fold of PKC-ε ε activation with respect to control
untreated cultures. Data represent the means ± SD of three inde-
pendent experiments. *p<0.05.
Figure 2. Maturative effect of TNF-α α, PKC-ε ε activator and inhibitor
peptides on HL-60 cells. HL-60 cells were incubated with control
scrambled (scr), PKC-ε ε activator (act) or inhibitor (inh) peptides
(22 µg/mL), used alone or in combination with TNF-α α (10 ng/mL)
for 72 hours and then analyzed for the surface expression of
CD14 myeloid antigen, by flow cytometry analysis, and for cell
morphology, by microscopic examination. In A, CD14 surface
expression is reported as percentage of positive cells, and data
are expressed as the mean ± SD of five independent experiments
performed in duplicate. *p<0.05. In B, a representative experi-
ment is shown: shadowed histograms represent cells stained
with Abs specific for the indicated surface antigen, whereas
unshadowed histograms represent the background fluorescence
obtained from the staining of the same cells with isotype-
matched control Abs. In C, the effects of TNF-α α and PKC-ε ε activa-
tor peptide on cell morphology are shown. HL-60 cells were
stained with May-Grünwald-Giemsa solution: asterisks indicate
cells with monocytic morphology. Representative fields of five
separate experiments are shown. Original magnification: X400.
UNT = untreated cells.
A
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Csents an excellent marker of monocytic maturation
since it is undetectable on the surface of monocyte
precursors and increases dramatically during their
differentiation to monocytes (Todd et al., 1981;
Zhang et al., 1994). While PKC-ε inhibitor peptide
had negligible effects on TNF-α-induced up-regula-
tion of CD14, PKC-ε activator peptide significantly
(p<0.05) counteracted the TNF-α up-regulation of
CD14 (Figure 2A-2B). Similarly, PKC-ε activator
peptide almost abrogated the TNF-α up-regulation of
CD11b, used as additional surface marker of mono-
cytic maturation (Secchiero et al.,2002).To confirm
these flow cytometric results by morphological analy-
ses,after 3 days of treatment with TNF-α plus PKC-
ε peptides,HL60 cells were cytocentrifuged and then
stained with May-Grunwald-Giemsa solution before
light microscopy examination.As shown in Figure 2C,
TNF-α plus PKC-ε activator peptide treated cultures
showed a decrease of cells with monocytic features,
such as condensation and cleavage of the nucleus,
with respect to TNF-α alone.
PKC-εactivator peptide counteracts the pro-apoptot-
ic activity of recombinant TRAIL 
Since the TNF family member TRAIL is a prom-
ising therapeutic agent for its ability to induce
apoptotic cell death in a variety of tumor cells,
including leukemias (Zauli and Secchiero, 2006),
we performed additional experiments to evaluate
the effects of combined treatments with either
PKC-ε activator or PKC-ε inhibitor peptides plus
recombinant TRAIL on the induction of HL-60 cell
apoptosis, evaluated by Annexin V/PI double stain-
ing and flow cytometry analysis.Increasing doses of
recombinant TRAIL were tested, in order to identi-
fy the concentration (100 ng/mL) able to promote
a significant increase of HL-60 apoptosis without
inducing the maximal apoptotic response (Figure
3A). Of note, neither PKC-ε activator nor PKC-ε
inhibitor peptides used alone showed significant
effects on HL-60 viability and apoptosis.When used
in combination with TRAIL, the PKC-ε inhibitor
peptide modestly but reproducibly (p<0.05)
increased the percentage of apoptosis in response to
TRAIL (Figure 3B). Conversely, PKC-ε activator
peptide significantly (p<0.05) counteracted the
ability of TRAIL to induce apoptosis (Figure 3B).
The ability of these peptides to modulate the apop-
totic activity of TRAIL was also confirmed by
Western blot analysis of PARP cleavage,a target of
caspase activity (Figure 3C).
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Figure 3. Effect of PKC-ε ε activator and inhibitor peptides on
TRAIL-mediated cytotoxicity in HL-60 cells. A: Dose-dependent
effect of TRAIL on apoptosis quantitatively evaluated by flow
cytometry after Annexin V/PI staining in HL-60 cells. Cells were
cultured for 24 hours with the indicated concentrations of TRAIL.
B: HL-60 cells were incubated with optimal concentrations (22
µg/mL) of PKC-ε ε activator (act) or inhibitor (inh) peptides, used
alone or in combination with recombinant TRAIL (0.1 µ µg/mL) and
the percentage of apoptosis was assayed by counting the number
of Annexin V positive cells. In A and B, data represent the means
± SD of five independent experiments performed in duplicate.
*p<0.05. C: PARP cleavage was also analyzed as apoptotic mark-
er. The full-length (115 kDa) and the cleaved forms (80 kDa;
arrowhead) of PARP of a representative experiment are shown.
Actin staining is shown as loading control. For both flow cytome-
try (B) and Western blot analysis (C) scrambled (scr) peptides
were used as negative controls. UNT = untreated cells.
A
B
CDiscussion
In this study, we have demonstrated for the first
time that PKC-ε activation significantly counteract-
ed the differentiation program induced by TNF-α
along the monocytic lineage.This aspect of PKC-ε
activity was not described before and it has impor-
tant therapeutic implications since induction of
mortality by terminal differentiation represents an
alternative approach to cytodestruction of cancer
cells by conventional antineoplastic agents,and has
important biological implications. In this respect,
retinoid acids are well known inducers of granulo-
cytic differentiation of primary acute promyelocyt-
ic leukemia (APL) blasts and leukemic cell lines
(Chambon, 1994). However, while some retinoids
are currently used in the treatment of the M3-type
of AML,agonists such as vitamin D3,able to induce
monocytic differentiation in other subtypes of AML
and in particular in M4- and M5-types, did not
demonstrate efficacy in clinical trials performed in
AML patients,mainly due to a secondary hypercal-
cemia thus limiting the dose of vitamin D3 that
could be administered (Bar-Shavit et al., 1983).
While the PKC-ε inhibitor peptide showed negli-
gible effects on the TNF-α-mediated induction of
leukemic maturation, this does not exclude that the
association of PKC-ε inhibitor peptide and pro-
maturative drugs might represent an important
therapeutic combination. In this respect, it is also
noteworthy that both PKC-ε inhibitor and activator
peptides were able to significantly modulate the
degree of apoptosis induced by TRAIL.The resist-
ance of leukemic cells to currently used therapies
occurs in part because leukemic cells safeguard
their survival through mechanisms that allow them
to escape death receptor-mediated apoptosis
(Hanahan and Weinberg, 2000). Much attention
has recently attracted the TNF family member
TRAIL for its ability to overcome resistance to
apoptosis in several tumors, including hematologi-
cal malignancies (Secchiero and Zauli, 2008).
While several studies have demonstrated that
TRAIL resistance in a variety of hematological
malignancies is mainly due to constitutively high
levels of c-FLIP or low levels of TRAIL receptors
(Secchiero and Zauli, 2008), we have here demon-
strated that also the selective activation of the
PKC-ε family member can markedly counteract the
susceptibility to TRAIL cytotoxicity in the sensitive
HL-60 cell line.Our current findings are in line with
those recently described by Gobbi et al. (2009),
who demonstrated that PKC-ε activation by phor-
bol esters confers resistance to apoptosis induction
in the K562 leukemic cell line. However, an impor-
tant differences between the study of Gobbi et al.
(2009) and our current data is that we have used
inhibitor and stimulatory peptides which might
have important future clinical applications.In fact,
Yonezawa et al. (2009) have recently reviewed the
potential use of PKC-ε specific peptides developed
by important pharmaceutical companies, which
specifically inhibit PKC-ε and ameliorate patholog-
ical conditions in a rodent insulin resistance model.
In summary, we propose that the ability of PKC-
ε to promote leukemogenesis might be twofold: on
one hand,it protects from TRAIL mediated apopto-
sis,perhaps by down-regulating Bid as demonstrat-
ed in other cancer cell models (Sivaprasad et al.,
2007) and, on the other hand, it counteracts matu-
ration along the monocytic lineage. Although the
physiological stimuli able to activate PKC-ε in the
bone marrow context are unknown,it is noteworthy
that leukemic cells, like normal hemopoietic cells,
survive and proliferate in the context of bone mar-
row niches (Li and  Neaves, 2006), it will be of
interest to investigate the effect of cell-to-cell con-
tact between bone marrow stromal cells and
leukemic cells on the activation state of PKC-ε.
Thus,while a potential role of PKC isoforms and in
particular of PKC-ε in promoting tumorigenesis
has been previously proposed,the novelty represent-
ed by this study is that we have demonstrated that
PKC-ε not only affect leukemic cell survival but
also leukemic maturation. Moreover, a clinical
implication of our study is that selective inhibition
of PKC-ε with inhibitor peptides, either to drugs
able to induce maturation or to death inducing lig-
ands or to combination thereof,should be taken into
account in order to improve their therapeutic
potential.
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